Meeting to be held on June 23-24 hosted by Oppenheimer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Promising Developments in Nurix Therapeutics’ BTK Degrader Drive Buy Rating
- Nurix Therapeutics Announces Positive Phase 1 Trial Results
- Nurix Therapeutics presents updated data from ongoing trial of bexobrutideg
- Optimistic Outlook on Nurix Therapeutics: Strategic Partnerships and Financial Gains Drive Buy Rating
- Oppenheimer bullish on Nurix as Sanofi opt-in, competitor data derisk STAT6